Proglucagon
- Name
- Proglucagon
- Accession Number
- DBCAT000120
- Description
The common precursor polypeptide of pancreatic GLUCAGON and intestinal GLUCAGON-LIKE PEPTIDES. Proglucagon is the 158-amino acid segment of preproglucagon without the N-terminal signal sequence. Proglucagon is expressed in the PANCREAS; INTESTINES; and the CENTRAL NERVOUS SYSTEM. Posttranslational processing of proglucagon is tissue-specific yielding numerous bioactive peptides.
- Drugs
Drug Drug Description Glucagon A form of recombinant glucagon used to treat hypoglycemia in diabetes mellitus and as a part of gastrointestinal imaging procedures. Liraglutide A GLP-1 analog used in the management of type 2 diabetes mellitus and prevention of cardiovascular complications associated with diabetes. Dulaglutide A GLP-1 agonist used to manage type 2 diabetes mellitus. rGLP-1 Investigated for use/treatment in congestive heart failure and diabetes mellitus type 2. Teduglutide A glucagon-like peptide-2 (GLP-2) analog used to treat patients with Short Bowel Syndrome (SBS) who require parenteral nutritional support. Albiglutide A GLP-1 agonist used to manage type 2 diabetes mellitus. Taspoglutide Taspoglutide is a pharmaceutical drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), under investigation for treatment of type 2 diabetes being codeveloped by Ipsen and Roche. In September 2010 Roche halted... Beinaglutide Beinaglutide is under investigation in clinical trial NCT03829891 (Study for Beinaglutide Versus Glargine Therapy in Glycemic Variability of Type 2 Diabetes Mellitus). BPI-3016 BPI-3016 is under investigation in clinical trial NCT03188848 (Dose Escalating Study of BPI-3016 in Healthy Subjects). Dasiglucagon A glucagon analog used to treat severe hypoglycemia in pediatric and adult patients with diabetes. - Drugs & Drug Targets